Prevalence of male and female permanent contraception and long-acting reversible contraceptives among a commercially insured population in the United States, 2010 to 2022 (2025)

Home

>

Section

>

Chapter

Full-Text Article emailed within 1 workday

Payments are secure & encrypted

References

Law, A.; Pilon, D.; Lynen, R.; Laliberté, Fçois.; Gozalo, L.; Lefebvre, P.; Duh, M.Sheng. 2016: Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population Reproductive Health 13(1): 96

Shewale, A.R.; Bhandari, N.R.; Kathe, N.; Hammond, D.; Painter, J.T. 2016: Characterization of Male and Female Users of Testosterone among the Commercially Insured Population in the United States Value in Health 19(3): A264-A265

Ferrante, N.D.; Newcomb, C.W.; Forde, K.A.; Leonard, C.E.; Torgersen, J.; Linas, B.P.; Rowan, S.E.; Wyles, D.L.; Kostman, J.; Trooskin, S.B.; Lo Re, V. 2022: The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population Open Forum Infectious Diseases 9(9): Ofac 445

Dilokthornsakul, P.; Valuck, R.J.; Nair, K.V.; Corboy, J.R.; Allen, R.R.; Campbell, J.D. 2016: Multiple sclerosis prevalence in the United States commercially insured population Neurology 86(11): 1014-1021

Latour, C.D.; Busse, C.E.; Dissanayake, M.V.; Dejene, S.Z.; Knittel, A.K.; Wood, M.E.; Kinlaw, A. 2023: New long-acting reversible contraceptive insertions more than doubled among a commercially insured, US-based outpatient population from 2010 to 2020 Pharmacoepidemiology and Drug Safety: 8-8

Law, A.; Yu, J.S.; Wang, W.; Lin, J.; Lynen, R. 2017: Trends and regional variations in provision of contraception methods in a commercially insured population in the United States based on nationally proposed measures Contraception 96(3): 175-182

Dumitriu, A.; Miles, G.; Crespo, A.; Maksimova, I.; Leiras, C.; Oliveri, D.; Yu, T.G.; Petruski-Ivleva, N. 2024: Pre- and post-diagnosis journey among commercially insured male and female Fabry disease patients in the United States Molecular Genetics and Metabolism 141

Blanchette, C.M.; Silver, H.; Petersen, H.; Kamble, S.; Meddis, D.; Gutierrez, B. 2009: Identification of a Threshold for High Utilization of Short Acting Beta2 Agonists in a Commercially Insured Adult Asthmatic Population in the United States Journal of Allergy and Clinical Immunology 123(2): S152-S152

Goldenberg, G.; Karagiannis, T.S.; Palmer, J.B.; Lotya, J.; O'Neill, C.B.; Kisa, R.M.; Herrera, V. 2015: Incidence and Prevalence of Basal cell Carcinoma in a Large United States Commercially Insured Population Value in Health 18(3): A193-A194

Lowe, P.; Rowlands, S. 2022: Long-acting reversible contraception: Targeting those judged to be unfit for parenthood in the United States and the United Kingdom Global Public Health 17(12): 3773-3784

Machicado, J.D.; Dudekula, A.; Tang, G.; Xu, H.; Wu, B.U.; Forsmark, C.E.; Yadav, D. 2019: Period prevalence of chronic pancreatitis diagnosis from 2001–2013 in the commercially insured population of the United States Pancreatology 19(6): 813-818

Law, A.; Pilon, D.; Lynen, R.; Laliberté, F.; Gozalo, L.; Lefebvre, P.; Duh, M.S. 2015: Impact of the introduction of newer long-acting reversible contraceptive (LARC) methods on LARC use in a commercially insured population Contraception 92(4): 374-375

Allison, B.A.; Ritter, V.; Flower, K.B.; Perry, M.F. 2021: Initiation of Long-Acting Reversible Contraception in Hospitalized Adolescents in the United States Hospital Pediatrics 11(7): 764-770

Das, M.; Anand, A.; Hossain, B.; Ansari, S. 2022: Inequalities in short-acting reversible, long-acting reversible and permanent contraception use among currently married women in India Bmc Public Health 22(1): 1264

Pace, L.E.; Dusetzina, S.B.; Murray Horwitz, M.E.; Keating, N.L. 2019: Utilization of Long-Acting Reversible Contraceptives in the United States After vs Before the 2016 US Presidential Election JAMA internal medicine 179(3): 444-446

Ferreira, J.M.; Monteiro, I.; Castro, S.; Villarroel, M.; Silveira, C.; Bahamondes, L. 2016: The use of Long Acting Reversible Contraceptives and the Relationship between Discontinuation Rates due to Menopause and to Female and Male Sterilizations Revista Brasileira de Ginecologia e Obstetricia: Revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 38(5): 210-217

Chiles, D.P.; Roberts, T.A.; Klein, D.A. 2016: Initiation and continuation of long-acting reversible contraception in the United States military healthcare system American Journal of Obstetrics and Gynecology 215(3): 328.E1-9

Hendrick, C.E.; Cone, J.N.; Cirullo, J.; Maslowsky, J. 2020: Determinants of Long-acting Reversible Contraception (LARC) Initial and Continued use among Adolescents in the United States Adolescent Research Review 5(3): 243-279

Moniz, M.H.; Chang, T.; Heisler, M.; Admon, L.; Gebremariam, A.; Dalton, V.K.; Davis, M.M. 2017: Inpatient Postpartum Long-Acting Reversible Contraception and Sterilization in the United States, 2008-2013 Obstetrics and gynecology 129(6): 1078-1085

Wu, L.L.; Mark, N.D.E. 2018: Could we Level the Playing Field? Long-Acting Reversible Contraceptives, Nonmarital Fertility, and Poverty in the United States RSF: The Russell Sage Foundation Journal of the Social Sciences 4(3): 144-166